跳至主要内容
临床试验/NCT02020161
NCT02020161Unknown4 期

Clinical Guidelines for APL Treatment

PETHEMA Foundation1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2012年6月最近更新:
适应症
干预措施

试验速览

阶段
4 期
发起方
入组人数
200
试验地点
1
主要终点
Recurrence within 1 year of treatment

研究概览

简要总结

Therapeutic guidelines for treatment of patients with de novo APL to be used by every institution that wants to follow them. All patients who are reported may be retrospectively analyzed

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • Genetic diagnosis of acute promyelocytic leukemia

排除标准

  • No exclusion criteria

研究组 & 干预措施

ATRA-Idarubicin

Experimental

干预措施: Atra (Drug)

ATRA-Idarubicin

Experimental

干预措施: Idarubicin (Drug)

ATRA-Idarubicin

Experimental

干预措施: methotrexate (Drug)

结局指标

主要结局

Recurrence within 1 year of treatment

时间窗: 3 years

Induction therapy with simultaneous ATRA (45 mg/m2 day until CR) and idarubicin (12 mg/m2 day on days 2, 4, 6 and 8 or 12 mg/m2 day on days 2, 4 and 6 in patients older than or equal to 60 years). Three monthly consolidation courses with ATRA Maintenance therapy with ATRA (45 mg/m2/d, days 1-15 every 3 months), and low dose chemotherapy with methotrexate (15 mg/m2/d, weekly) and 6-mercaptopurine (50 mg/m2/d) for two years.

次要结局

未报告次要终点

研究者

发起方
PETHEMA Foundation
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Clinical Guidelines for APL Treatment | 临床试验